

BLOOD

*The Journal of
The American Society of
Hematology*

VOL 75, NO 9

CONTENTS

MAY 1, 1990

REVIEW ARTICLE

- Review: Molecular Basis of Vitamin K-Dependent γ -Carboxylation *B. Furie and B.C. Furie* 1753

RAPID COMMUNICATION

- Point Mutations in the Uroporphyrinogen III Synthase Gene in Congenital Erythropoietic Porphyria (Günther's Disease).....*J.-C. Deybach, H. de Verneuil, S. Boulechar, B. Grandchamp, and Y. Nordmann* 1763

CLINICAL INTERVENTION AND THERAPEUTIC TRIALS

- Treatment of Poor-Prognosis, Newly Diagnosed Acute Myeloid Leukemia With Ara-C and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor ...*E.H. Estey, D. Dixon, H.M. Kantarjian, M.J. Keating, K. McCredie, G.P. Bodey, R. Kurzrock, M. Talpaz, E.J. Freireich, A.B. Deisseroth, and J.U. Gutterman* 1766

HEMATOPOIESIS

- Clonal Studies in the Myelodysplastic Syndrome Using X-Linked Restriction Fragment Length Polymorphisms*A. Tefferi, S.N. Thibodeau, and L.A. Solberg, Jr* 1770
- Regulation of Human Eosinophil Precursor Production by Cytokines: A Comparison of Recombinant Human Interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh Granulocyte-Macrophage Colony-Stimulating Factor*E.J. Clutterbuck and C.J. Sanderson* 1774
- Human Colony-Stimulating Factor 1 (CSF-1) Receptor Confers CSF-1 Responsiveness to Interleukin-3-Dependent 32DCL3 Mouse Myeloid Cells and Abrogates Differentiation in Response to Granulocyte CSF*J.-y. Kato and C.J. Sherr* 1780
- In Vitro and In Vivo Hematopoietic Effect of Mutant Human Granulocyte Colony-Stimulating Factor*M. Okabe, M. Asano, T. Kuga, Y. Komatsu, M. Yamasaki, Y. Yokoo, S. Itoh, M. Morimoto, and T. Oka* 1788

HEMOSTASIS AND THROMBOSIS

- A Monoclonal Antibody Specific for Two-Chain Urokinase-Type Plasminogen Activator. Application to the Study of the Mechanism of Clot Lysis With Single-Chain Urokinase-Type Plasminogen Activator in Plasma*P.J. Declerck, H.R. Lijnen, M. Verstreken, H. Moreau, and D. Collen* 1794
- Human Endothelial Cells Synthesize, Process, and Secrete Fibronectin Molecules Bearing an Alternatively Spliced Type III Homology (ED1)*J.H. Peters, L.A. Sporn, M.H. Ginsberg, and D.D. Wagner* 1801
- Analyses of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura-Prone Mice by Platelet Transfer Experiments Between (NZW \times BXSB) F_1 and Normal Mice*H. Mizutani, T. Furubayashi, A. Kuriu, H. Take, Y. Tomiyama, H. Yoshida, Y. Nakamura, M. Inaba, Y. Kurata, T. Yonezawa, S. Tarui, and S. Ikehara* 1809

IMMUNOBIOLOGY

- Regulation of Autoimmune Anti-Platelet Antibody-Mediated Adhesion of Monocytes to Platelet GPIIb/GPIIIa: Effect of Armed Monocytes and the Mac-1 Receptor*K.B. Hymes, M.P. Schuck, and S. Karpatskin* 1813
- Human Blood Basophils Synthesize Interleukin-2 Binding Sites.....*H. Stockinger, P. Valent, O. Majdic, P. Bettelheim, and W. Knapp* 1820

Applicants: David J. Pinsky
U.S. Serial No.: 09/374,586
Filed: August 13, 1999
Group Art Unit: 1633

(Continued on following page)

(Contents continued)

NEOPLASIA

- Low Expression of Lymphocyte Function-Associated Antigen (LFA)-1 and LFA-3 Adhesion Molecules Is a Common Trait in Burkitt's Lymphoma Associated With and Not Associated With Epstein-Barr Virus *M. Billaud, F. Rousset, A. Calender, M. Cordier, J.-P. Aubry, V. Laisse, and G.M. Lenoir* 1827
- High Prevalence of T-Cell Receptor V δ 2-(D)-D δ 3 or D δ 1/2-D δ 3 Rearrangements in B-Precursor Acute Lymphoblastic Leukemias *A. Biondi, P.F. di Celle, V. Rossi, G. Casorati, G. Matullo, G. Giudici, R. Foa, and N. Migone* 1834
- Chromosomal Abnormalities in Untreated Patients With Non-Hodgkin's Lymphoma: Associations With Histology, Clinical Characteristics, and Treatment Outcome *H.C. Schouten, W.G. Sanger, D.D. Weisenburger, J. Anderson, and J.O. Armitage for the Nebraska Lymphoma Study Group* 1841
- Localization of Breakpoints by Polymerase Chain Reactions in Burkitt's Lymphoma With 8;14 Translocations *B. Shiramizu and I. Magrath* 1848
- Blood Kinetics, Tissue Distribution, and Radioimaging of Anti-Common Chronic Lymphatic Leukemia Antigen (cCLLa) Monoclonal Antibody CLL₂ in Mice Transplanted With cCLLa-Bearing Human Leukemia Cells *G.B. Faguet, J.F. Agee, and J.T. DiPiro* 1853

RED CELLS

- Fetal Calf Serum Contains Activities That Induce Fetal Hemoglobin in Adult Erythroid Cell Cultures *P. Constantoulakis, B. Nakamoto, Th. Papayannopoulou, and G. Stamatoyannopoulos* 1862
- Serum Transferrin Receptor: A Quantitative Measure of Tissue Iron Deficiency *B.S. Skikne, C.H. Flowers, and J.D. Cook* 1870
- Reticulocytes II: Reexamination of the In Vivo Survival of Stress Reticulocytes *N.A. Noble, Q.-P. Xu, and L.L. Hoge* 1877
- Hemoglobin Birmingham and Hemoglobin Galicia: Two Unstable β Chain Variants Characterized by Small Deletions and Insertions *J.B. Wilson, B.B. Webber, H. Hu, A. Kutlar, F. Kutlar, J.F. Codrington, J.T. Prchal, K.M. Hall, J.M². de Pablos, I. Rodriguez, and T.H.J. Huisman* 1883

TRANSPLANTATION

- Cytomegalovirus Infection After Autologous Bone Marrow Transplantation: Occurrence of Cytomegalovirus Disease and Effect on Engraftment *P. Reusser, L.D. Fisher, C.D. Buckner, E.D. Thomas, and J.D. Meyers* 1888

CORRESPONDENCE

- Serum Levels of Tumor Necrosis Factor α in Patients Treated With Granulocyte-Macrophage Colony-Stimulating Factor 1895
- Therapy of Chronic Idiopathic Thrombocytopenic Purpura in Adults 1896
- Interleukin-6 and Phospholipase A₂ in Sepsis 1897
- Lymphocyte Phenotype After Treatment for Leukemia 1898

SPECIAL DEPARTMENTS

- Announcements 1900
- Information for Contributors xxv

(Continued on following page)

(Contents continued)

All manuscripts submitted to BLOOD and subsequently accepted for publication will be assessed a \$50.00 charge per published page. This charge is necessary to offset the increasing costs of publication.

All manuscripts submitted for consideration for publication in BLOOD should be sent to: Arthur W. Nienhuis, M.D., Editor, BLOOD, The Journal of the American Society of Hematology, 9650 Rockville Pike, Bethesda, MD 20814. For other information, call (301) 571-1895.

The American Society of Hematology certifies that the continuing medical education offering provided by BLOOD, The Journal of The American Society of Hematology, meets the criteria for up to 22 hours of credit in Category 5(a) for the Physician's Recognition Award of the American Medical Association.

Cover photo courtesy of B. Furie and B.C. Furie. See the report "Molecular Basis of Vitamin K-Dependent γ -Carboxylation," page 1753.

Analyses of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura-Prone Mice by Platelet Transfer Experiments Between (NZW \times BXSB) F_1 and Normal Mice

By Hajime Mizutani, Takayasu Furubayashi, Akira Kuriu, Hironori Take, Yoshiaki Tomiyama, Hirotugu Yoshida, Yutaka Nakamura, Muneo Inaba, Yoshiyuki Kurata, Takeshi Yonezawa, Seiichiro Tarui, and Susumu Ikehara

Male (NZW \times BXSB) F_1 (W/B F_1) mice, which develop lupus nephritis, myocardial infarction, and thrombocytopenia, showed reduced platelet lifespan (PLS) and increased platelet-associated antibody (PAA) values. There were statistically significant correlations between the increase in PAA values and either the reduction in PLS or the decrease in platelet counts. This and the results of platelet transfer experiments between old male W/B F_1 mice and either female W/B F_1 or normal BALB/c mice indicate that PAAs on the platelet surface play a crucial role in the

destruction of platelets in W/B F_1 mice. The mechanism of thrombocytopenia observed here appears similar to that of human idiopathic thrombocytopenic purpura (ITP). Therefore, we think that W/B F_1 mice are a potentially useful animal model for investigating the effectiveness and mode of action of therapeutic agents in human ITP, and that they may provide additional information on the basic mechanisms of this autoimmune phenomenon.

© 1990 by The American Society of Hematology.

IT IS THOUGHT that the autoimmune mechanism is involved in the development of chronic idiopathic (immune) thrombocytopenic purpura (ITP); the binding of circulating anti-platelet antibodies to platelets results in their destruction by phagocytic cells in the reticuloendothelial system.^{1,2} The presence of anti-platelet antibodies, and a markedly reduced platelet lifespan (PLS), have been among the accepted clinical features of human ITP.^{3,4}

We recently reported that male (NZW \times BXSB) F_1 (W/B F_1) mice, which develop lupus nephritis with myocardial infarction, show thrombocytopenia with age, and that this is probably due to the presence of both platelet-associated antibodies (PAAs) and circulating anti-platelet antibodies.⁵ In this study, we investigate the PLS of W/B F_1 mice and performed platelet transfer experiments between male W/B F_1 mice and either female W/B F_1 or normal BALB/c mice. We found that the platelets of male W/B F_1 mice show significantly reduced lifespans with age, and that there are statistically significant correlations between the increased PAA values and either the reduced PLS or the decreased platelet counts.

MATERIALS AND METHODS

Mice. BALB/c, BXSB, and NZW mice were originally purchased from Jackson Laboratories (Bar Harbor, ME). W/B F_1 (hybrid of NZW female and BXSB male) were raised under specific pathogen-free conditions in the animal facility of the Nippon Shinyaku Research Laboratories (Kyoto, Japan).

Platelet labeling and platelet kinetics studies. ¹¹¹In-tropolone was used for the labeling of platelets by the method of Dewanjee et al.⁶ It was made by mixing 100 μ L of ¹¹¹In-0.04 mol/L HCl (Japan Medi-physics Co, Hyogo, Japan, 1 mCi/mL) and the same volume of tropolone solution (Sigma Co, St Louis, MO) with acid-citrate-dextrose (ACD-A, pH 4.5, 0.01 mol/L)-saline at a concentration of 2 mg/mL, then incubated for 5 minutes at room temperature. Blood (1.5 mL) was obtained from the retro-orbital plexus of ether-anesthetized mice in ACD-A. Platelets were isolated by differential centrifugation at room temperature, first at 300 \times g for 5 minutes to obtain platelet-rich plasma, which was then washed three times at 2,000 \times g for 15 minutes. Contaminating red blood cells (RBCs) were removed by centrifugation at 100 \times g for 5 minutes. Platelets (1×10^6) were resuspended in 1 mL of ACD-A-saline (pH 7.6), to which 100 μ L of ¹¹¹In-tropolone was added. The mixture was kept under constant agitation for 30 minutes at room temperature, and the radiolabeled platelets were then washed three times in ACD-A-

saline and resuspended in 1.0 mL of saline. The labeling indices ranged from 50% to 70%. Recipient mice were injected intravenously (IV) with the radiolabeled platelets (3 to 5 μ Ci in 0.2 mL). Blood (15 μ L) was taken 1 minute, 30 minutes, 1 hour, 2 hours, 4 hours, 24 hours, and 48 hours after injection. The radioactivity was counted using a well-typed scintillation counter (Aloka Co, Tokyo, Japan).

Data analysis. The mean platelet survival was estimated by calculating the rate of platelet disappearance from circulation using multiple-hit model analyses, as recommended by the International Committee for Standardization in Hematology.⁷

Platelet-associated antibodies. Because of the difficulty of obtaining sufficient blood samples, we used a modified method of platelet suspension immunofluorescence test (PSIFT) for PAA.^{5,8} Briefly, platelet suspensions were obtained from EDTA blood (50 μ L) by centrifugation as mentioned above. After washing three times in 5 mmol/L EDTA-phosphate-buffered saline (PBS) (pH 6.8), the platelets were suspended in 1% paraformaldehyde solution for 5 minutes. Platelets were resuspended in 100 μ L of EDTA-PBS to a platelet count of $3 \times 10^5/\mu$ L. Then they were incubated with 5 μ L of FITC-conjugated goat anti-mouse immunoglobulin (Ig) (Becton Dickinson, Sunnyvale, CA) for 30 minutes at room temperature. After final washing, samples were analyzed on a FACScan (Becton

From the Second Department of Internal Medicine, Osaka University Medical School, and the Department of Transfusion, Osaka University Hospital; First Department of Pathology, Kansai Medical University, Osaka; and Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan.

Submitted May 23, 1989; accepted January 9, 1990.

Supported in part by grants from the Japanese Ministry of Health and Welfare; Naito Foundation; Mitsubishi Foundation; a Grant-in-aid from the Mochida Memorial Foundation for Medical and Pharmaceutical Research; a grant from Suzuken Memorial Foundation; the Science Research Promotion Fund of the Japan Private School Promotion Foundation; and a Grant-in-aid for cancer research, 01015110 (1989) and a Grant-in-aid for general scientific research, 63480147 (1988) from the Ministry of Education, Science, and Culture.

Address reprint requests to Hajime Mizutani, MD, Second Department of Internal Medicine, Osaka University Hospital, Fukushima, Fukushima-ku, Osaka 553, Japan.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1990 by The American Society of Hematology.
0006-4971/90/7509-0015\$3.00/0

Table 1. Platelet Lifespans, Platelet-Associated Antibodies, and Platelet Counts in W/B F₁ Mice

Mouse	Age (mo)	Sex	No.	Platelet Count ($\times 10^3/\mu\text{L}$)	PAA* (%)	Platelet Lifespan† (d)
BALB/c	6	M	6	1,225 \pm 153	1.6 \pm 1.0	2.11 \pm 0.28
NZW	6	M	5	1,005 \pm 113	1.6 \pm 0.9	1.62 \pm 0.61
BXSB	4	F	5	962 \pm 91	1.9 \pm 0.5	1.57 \pm 0.33
W/B F ₁	3	F	3	1,012 \pm 55	3.0 \pm 2.4	1.44 \pm 0.21
W/B F ₁	1	M	4	1,063 \pm 114	1.4 \pm 1.2	1.20 \pm 0.40
W/B F ₁	2	M	4	1,021 \pm 140	10.1 \pm 6.1‡	0.56 \pm 0.04‡
W/B F ₁	3	M	4	842 \pm 57	18.9 \pm 15.0‡	0.25 \pm 0.11‡
W/B F ₁	4	M	4	612 \pm 104‡	15.9 \pm 5.8‡	0.09 \pm 0.03‡
W/B F ₁	5	M	4	502 \pm 93‡	25.5 \pm 4.6‡	0.12 \pm 0.03‡
W/B F ₁	6	M	4	491 \pm 72‡	49.9 \pm 5.2‡	0.11 \pm 0.04‡

*Platelets were labeled with FITC-conjugated goat anti-mouse Ig and analyzed using a FACScan.

†Platelet lifespan was examined by transferring ^{111}In -labeled platelets from donor mice to age-matched mice of the same strain.

‡ $P < .001$ versus data in young (1 month) F₁ mice.

Dickinson) by gating to exclude debris. Unlabeled platelets were first analyzed to determine the highest level of autofluorescence, and then the percentage of positive platelets was calculated from the total platelet count above the level of autofluorescence.

Platelet counts. Blood (20 μL) was diluted in buffer containing ammonium oxalate (Unopette kits, Becton Dickinson). Platelets were counted using a hemacytometer under a phase-contrast microscope.

RESULTS

Table 1 summarizes the platelet counts, PAA values, and platelet survivals of variously aged W/B F₁ mice. Male W/B




Fig 1. Correlations between increased PAA values (O—O) and either reduced PLS (O---O) or decreased platelet counts (●—●) in male W/B F₁ mice. N values for the individual points are shown in Table 1.




Fig 2. Relationships between age and platelet counts, PAA values, and PLS in male W/B F₁ mice.

F₁ mice gradually showed thrombocytopenia with age, and a significant decrease in platelet counts was observed in mice aged more than 4 months. In contrast, the parent mice (NZW and BXSB) and female W/B F₁ (3 months) mice showed normal platelet counts, as did normal BALB/c mice. PAAs were positive in more than 2-month-old W/B F₁ mice; percent-positive platelets increased with age (Table 1 and Fig 1). The mean platelet survival of BALB/c mice was 2.11 days. Male W/B F₁ mice more than 2 months of age showed significantly reduced PLS compared with male W/B F₁ mice at the age of 1 month. As shown in Fig 2, there were statistically significant correlations between the increase in percent-positive values of PAAs and either the reduction in PLS ($r = -.80$, $P < .01$) or the decrease in platelet counts ($r = -.69$, $P < .01$). There was also a statistically significant correlation between the reduction in PLS and the decrease in platelet counts ($r = .82$, $P < .01$). It should be noted that the reduction in PLS and the increase in PAA values were observed in male W/B F₁ mice even at the age of 2 months, although the platelet count was almost normal.

To elucidate whether the reduced PLS was due to the abnormality of the platelets themselves in male W/B F₁ mice or plasma factors, we performed platelet transfer experiments between male W/B F₁ mice and either female W/B F₁ or normal BALB/c mice.

As shown in Table 2, normal BALB/c (6 months) and female W/B F₁ (3 months) mouse platelets that had been transferred to male W/B F₁ (6 months) mice were immediately cleared from circulation after injection; PLS were 0.15 ± 0.28 days and 0.21 ± 0.04 days. Platelets transferred

Table 2. Platelet Transfer Experiments Between Male W/B F₁ and Either Female W/B F₁ or Normal BALB/c Mice

Donor Mouse				Recipient Mouse				
Mouse	Sex	Age (mo)	PAA (%)	Mouse	No. Examined	Sex	Age (mo)	Platelet Survival (d)
BALB/c	M	6	1.6 ± 1.0	BALB/c	6	M	6	1.6 ± 1.0
BALB/c	M	6	1.7	W/B F ₁	4	M	6	2.11 ± 0.28
W/B F ₁	M	6	41.2	BALB/c	4	M	6	0.15 ± 0.03*
W/B F ₁	F	3	1.9	W/B F ₁	4	M	6	0.11 ± 0.02*
W/B F ₁	M	6	39.0	W/B F ₁	4	M	6	0.21 ± 0.04*
						F	3	0.12 ± 0.04*
								3.0 ± 2.4

*P < .001 versus data of BALB/c (6 months) platelet survival transferred to BALB/c mice (6 months).

from male W/B F₁ mice (6 months) to BALB/c mice (6 months) were also cleared from circulation immediately (0.11 ± 0.02 days). Platelets transferred from male W/B F₁ mice (6 months) to female W/B F₁ mice (3 months) were also cleared from circulation immediately (0.12 ± 0.04 days).

DISCUSSION

In this study, we demonstrate that male W/B F₁ mice develop thrombocytopenia, increased anti-platelet antibodies on their platelet surface, and reduced platelet lifespans with age. There were statistically significant correlations between the increased PAA values and either the reduced PLS or the decreased platelet counts. From the present results and our previous findings of megakaryocytosis in the bone marrow,⁵ we consider that the mechanism of thrombocytopenia in male W/B F₁ mice is due to increased PAAs resulting in the acceleration of platelet destruction, but not to decreased platelet production.

W/B F₁ mice are well-known for developing systemic lupus erythematosus (SLE)-like diseases and their expression of high levels of circulating immune complexes (CICs).⁹⁻¹¹ CIC-mediated thrombocytopenia was also demonstrated in patients with SLE.¹² Moreover, it is known that the CICs bind to specific glycoproteins in some drug-induced thrombocytopenia.¹³ Although murine platelets have no Fc receptor, they possess C3b receptors capable of binding to CICs.^{14,15} It is conceivable that CICs are involved in the reduced PLS in these mice. However, other typical SLE-prone mice, such as NZB, MRL/lpr, and BXSB, which show high CIC levels, have normal platelet counts.^{16,17} Furthermore, the sera from BXSB and MRL/lpr mice do not bind to the platelets of BALB/c.⁵ From these results, it seems unlikely that increased PAAs in W/B F₁ mice are due to the binding of CICs to the platelet surface. Therefore, we think that CICs do not

play an important role in platelet destruction in W/B F₁ mice. In fact, CICs are often observed in patients with ITP, but it is known that they have little influence on platelet destruction.^{18,19}

Significantly reduced PLS and increased PAA values were noted in male W/B F₁ mice even at the age of 2 months, although their platelet counts were almost normal. We speculate that platelet destruction was mild and compensated for by increased production of platelets in these mice of that age. Similar kinetic observations have also been reported in patients with ITP after splenectomy.²⁰

The immediate clearance of female W/B F₁ and normal BALB/c platelets transferred to male W/B F₁ mice indicates the presence of circulating anti-platelet antibodies in the plasma of old male W/B F₁ mice, as we previously demonstrated.⁵ Furthermore, old male W/B F₁ mouse platelets transferred to BALB/c mice were also cleared from circulation immediately. As shown in Fig 2, the significant correlations between the increase in PAA values and the decrease in PLS or platelet counts strongly suggest that the immediate clearance of transferred platelets is due to the presence of antibodies (PAAs and circulating anti-platelet antibodies), but not due to an abnormal host environment, such as hyperfunction of the reticuloendothelial system in old male W/B F₁ mice.

We have no data to show conclusively the presence of autoantibodies to platelets. We are not only in the process of verifying to which platelet epitopes antibodies are produced, but also clarifying where and how the platelets of W/B F₁ mice are destroyed.

Because the mechanism of thrombocytopenia observed here appears similar to that of human ITP, this animal could serve as a useful model for investigating the effectiveness and mode of action of new therapeutic agents in human ITP.

REFERENCES

- McMillan R: Chronic idiopathic thrombocytopenic purpura. *N Engl J Med* 304:1135, 1981
- Karpatsin S: Autoimmune thrombocytopenic purpura. *Semin Hematol* 22:260, 1985
- Tsubakio T, Kurata Y, Yonezawa T, Kitani T: Quantification of platelet-associated IgG with competitive solid-phase enzyme immunoassay. *Acta Haematol* 66:251, 1981
- Stoll D, Cines DB, Aster RH, Murphy S: Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. *Blood* 65:584, 1985
- Oyaizu N, Yasumizu R, Miyama-Inaba M, Nomura S, Yoshida H, Miyawaki S, Shibata Y, Mitsuoka S, Yasunaga K, Morii S, Good RA, Ikehara S: (NZW × BXSB)F₁ mouse: A new animal model of idiopathic thrombocytopenic purpura. *J Exp Med* 167:2017, 1988
- Dewanjee MK, Rao SA, Rosemark JA: Indium-111 tropolone, a new tracer for platelet labeling. *Radiology* 145:149, 1982
- International Committee for Standardization in Hematology: Recommended methods for Indium-111 platelet survival studies. *J Nucl Med* 29:564, 1988
- von dem Borne AEGK, Helmerhorst FM, Van Leeuwen EF, Pegels HG, von Riesz E, Engelfriet CP: Autoimmune thrombocytopenic purpura: Detection of platelet autoantibodies with the suspension immunofluorescence test. *Br J Haematol* 45:319, 1980
- Hang LM, Izui S, Dixon FJ: (NZW × BXSB)F₁ hybrid. A

- model of acute lupus and coronary vascular disease with myocardial infarction. *J Exp Med* 154:216, 1981
10. Hang L, Stephen-Larson PM, Henry JP, Dixon FJ: Transfer of renovascular hypertension and coronary heart disease by lymphoid cells from SLE-prone mice. *Am J Pathol* 115:42, 1984
11. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. *Adv Immunol* 37:269, 1985
12. Kasai N, Parbtani A, Cameron JS, Yewdall V, Shephard P, Verroust P: Platelet-aggregating immune complexes and intraplatelet serotonin in idiopathic glomerulonephritis and systemic lupus. *Clin Exp Immunol* 43:64, 1981
13. Kunicki TJ, Russell N, Nurden AT, Aster RH, Caen JP: Further studies of the human platelet receptor for quinidine and quinidine-dependent antibodies. *J Immunol* 126:398, 1981
14. Pfueller SL: Immunology of the platelet surface, in George JN, Nurden AT, Phillip DR (eds): *Platelet Glycoproteins*. New York, NY, Plenum, 1985, p 327
15. Kinoshita T, Lavoie S, Nussenzweig V: Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type I (CR1). *J Immunol* 134:2564, 1985
16. Grau GE, Puthavathana S, Izui S, Lambert PH: Induction of acute thrombocytopenia and infection of megakaryocyte by Rauscher murine leukemia virus reflect the genetic susceptibility to leukemogenesis. *J Exp Med* 157:1028, 1983
17. Casey TP, Howie JB: Autoimmune hemolytic anemia in NZB/B1 mice treated with the corticosteroid drug betamethasone. *Blood* 25:423, 1965
18. Kiefel V, Spaeth P, Mueller-Eckhardt C: Immune thrombocytopenic purpura: Autoimmune or immune complex disease? *Br J Haematol* 64:57, 1986
19. Kurata Y, Hayashi S, Aochi H, Nagamine K, Oshida M, Mizutani H, Tomiyama Y, Tsubakio T, Yonezawa T, Tarui S: Analysis of antigen involved in circulating immune complexes in patients with idiopathic thrombocytopenic purpura. *Clin Exp Immunol* 67:293, 1987
20. Harker LA: Thrombokinetis in idiopathic thrombocytopenic purpura. *Br J Haematol* 19:95, 1970